Can anti-cancer drugs be used as an effective therapy for the treatment of Alzheimer’s disease?

Background Worldwide, around 50 million people have dementia. According to the World Health Organization reports, this number is expected to increase threefold by 2050. Alzheimer’s disease (AD) is the most common type of dementia, which is characterised by deterioration in cognition and behaviour. The underlying aetiopathogenesis of AD is still little understood. The amyloid plaques theory and tau hyperphosphorylation are […]

Read More…

A new generation of induced pluripotent stem cells for regenerative medicine

Dr Schrepfer and Dr Deuse conducting their stem cell research

Embryonic stem cells or induced pluripotent stem cells are unlimited sources for the generation of cell derivatives for the regeneration of failing organs. However, such cell transplants are subject to immune rejection by the recipient’s immune system. Drs Sonja Schrepfer and Tobias Deuse from the University of California, San Francisco, have developed a new generation of immune-edited induced pluripotent stem […]

Read More…

An age-old problem: How SENS Research Foundation is looking at age-related disease in a new way

SENS Research Foundation funds innovative gerontology research around the world.

Despite time, energy and money being poured into age-related disease research around the world, humans are yet to find cures for illnesses such as Alzheimer’s, cardiovascular disease and diabetes. SENS Research Foundation believe this is because current research is approaching the problem from the wrong angle. Research Outreach found out more from the Foundation’s Chief Science Officer and co-founder Dr […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION